Dyskinesias and motor fluctuations were present in 6.9% and 4.9% of PARK-LRRK2 patients, respectively (with median disease duration of 14 and 13.5 years), relatively low compared with the widely quoted estimate of ~10% of levodopa-treated PD patients per year developing motor response complications53–55. Here, LRRK2 is linked to Parkinson disease.